RESEARCH - TNF blockers may not cause cancer after all

[Guest guest]

Tumor Necrosis Factor Blockers May Not Cause Cancer After All

Posted 10/10/2006

Medscape

Patients with rheumatoid arthritis (RA), an autoimmune,

inflammatory disease marked by progressive joint and organ damage, face a

high risk of developing cancer. Their vulnerability, especially to lymphoma

and leukemia, may be due to the nature of RA. Disease-modifying

antirheumatic drugs (DMARDs) - including tumor necrosis factor alpha (TNFa)

antagonists, a type of biologic DMARD - have also been implicated. TNF

blockers, which work by attaching to and impeding chemical messengers behind

inflammation, have had a significant impact on the treatment of RA. They

have also been linked to lymphoma among users. In fact, reports of lymphoma

prompted the Food and Drug Administration to mandate adding a cancer risk

warning to the labels of three TNF blockers: etanercept (Enbrel), infliximab

(Remicade), and adalimumab (Humira).

Motivated by persistent concerns and inconclusive studies,

researchers at Harvard Medical School's Brigham and Women's Hospital set out

to investigate the association between treatment with TNF blockers and

occurrence of cancer in a large sample of patients with RA. Their results,

featured in the September 2006 issue of Arthritis & Rheumatism

(http://www.interscience.wiley.com/journal/arthritis), indicate that

biologic DMARD therapy poses no greater risk for cancer than therapy with a

standard prescription DMARD, methotrexate (MTX).

The researchers focused on 7,830 RA patients, age 65 and older,

drawn from healthcare databases in New Jersey, Pennsylvania, and British

Columbia, Canada. Subjects included 1,152 biologic DMARD users and 7,306 MTX

users. Of those treated with a biologic DMARD, 64 percent had used

etanercept, 33 percent had used infliximab, and the remaining 2 percent had

used anakinra (Kineret). 55 percent had previously used MTX and 39 percent

were receiving MTX when they began anti-TNF therapy.

Based on medical utilization information, the researchers

measured every subject's general health and RA-related characteristics

during the 6-month period before exposure to either a biologic DMARD or MTX.

In general, biologic DMARD users had more severe RA than MTX users. No

subject had a diagnosis of any cancer before starting their prescribed drug

treatment. Each subject was followed after beginning use of either a

biologic DMARD or MTX, with attention to diagnosis of cancer followed by any

course or combination of palliative care, biopsy, radiation, chemotherapy,

or surgery. Using time-varying propensity scores to adjust for a wide range

of possible factors and stratified proportional hazards regression,

researchers estimated the effects of biological DMARDs on cancer.

From their rigorous definition of cancer, researchers identified

a total of 11 cancers of the blood and lymphatic systems and 46 cancerous

tumors during 2,940 person-years of biologic DMARD use, and 58 cancers of

the blood and lymphatic systems and 558 tumors during 30,300 person-years of

MTX use. Comparing biologic DMARD users with MTX users, the hazard ratio was

1.37 for blood-related cancers and 0.91 for solid tumors. The overall

difference in estimated cancer risk was less than 5 percent between RA

patients treated with a TNF blocker and those treated with a standard DMARD.

" We found no significant increase in the risk of cancers in

biologic DMARD users, " notes the study's lead authors, Soko Setoguchi, M.D.

Dr.P.H and Sebastian Schneeweiss, M.D, Sc.D. " Our data indicate that it is

unlikely that RA patients who have received biologic agents have a much

greater risk of lymphoproliferative disorders, hematologic malignancies, and

solid tumors compared with MTX users. " Drs, Setoguchi and Schneeweiss,

however, acknowledges the challenge of studying the effects of a relatively

novel therapy on rare forms of blood cancer, as well as the need for ongoing

studies into the risks and benefits associated with anti-TNF therapy.

Item is available via Wiley InterScience at

http://www.interscience.wiley.com/journal/arthritiscare.

Arthritis Care. 2006;54(9):2757-2764. ©2006 Wiley InterScience

http://www.medscape.com/viewarticle/545077

Not an MD

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org